Recent research suggests that certain weight-loss drugs, specifically glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and tirzepatide, may significantly reduce hospital admissions related to alcohol use. These findings come from several US-based studies analyzing data from tens of thousands of adults with histories of alcoholism or alcohol use disorder.
One comprehensive analysis of 40,703 individuals who began treatment with either semaglutide (branded as Wegovy or Ozempic) or tirzepatide (known as Mounjaro) between 2018 and 2024 found that GLP-1 drugs lowered the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes medications. Among those using these drugs specifically for weight loss, the risk reduction increased to 32 percent relative to other obesity treatments. Moreover, in subgroups of patients with type 2 diabetes or obesity combined with alcohol problems, reductions in alcohol-related hospital admissions reached as high as 63 to 65 percent.
GLP-1 agonists simulate a natural hormone involved in appetite suppression, making patients feel fuller and potentially reducing cravings. Researchers believe this mechanism may extend to lowering alcohol cravings by affecting the brain's reward pathways common to both overeating and addiction. Supporting this, a randomized clinical trial involving 48 participants with alcohol use disorder reported that low-dose semaglutide injections reduced weekly alcohol consumption by 41 percent and decreased cravings by 40 percent.
Despite promising results, experts caution that current evidence is largely observational and that more rigorous clinical trials are necessary before these medications can be firmly established as treatments for alcohol use disorder. Some also point out potential confounding factors, such as socioeconomic status and differential access to these relatively expensive medications, which may influence study outcomes. For instance, patients with better health insurance or higher incomes are more likely to afford GLP-1 therapies, which could impact the results.
Hospital admissions related to alcohol remain a significant public health issue, with more than one million such cases recorded in England alone in 2023-24. Researchers note that while GLP-1 drugs show potential in reducing alcohol-related harm, further investigation is required to better understand their role within broader addiction treatment frameworks.
Overall, while the studies add to a growing body of evidence suggesting GLP-1 agonists may benefit individuals struggling with alcoholism, experts emphasize the need for additional controlled trials to confirm efficacy and safety in this context.